224 related articles for article (PubMed ID: 7689822)
1. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
[TBL] [Abstract][Full Text] [Related]
2. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
[TBL] [Abstract][Full Text] [Related]
3. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
St Clair MH; Martin JL; Tudor-Williams G; Bach MC; Vavro CL; King DM; Kellam P; Kemp SD; Larder BA
Science; 1991 Sep; 253(5027):1557-9. PubMed ID: 1716788
[TBL] [Abstract][Full Text] [Related]
4. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
5. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
[TBL] [Abstract][Full Text] [Related]
7. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
Larder BA; Kemp SD
Science; 1989 Dec; 246(4934):1155-8. PubMed ID: 2479983
[TBL] [Abstract][Full Text] [Related]
8. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
[TBL] [Abstract][Full Text] [Related]
9. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
Shafer RW; Kozal MJ; Winters MA; Iversen AK; Katzenstein DA; Ragni MV; Meyer WA; Gupta P; Rasheed S; Coombs R
J Infect Dis; 1994 Apr; 169(4):722-9. PubMed ID: 8133086
[TBL] [Abstract][Full Text] [Related]
11. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
Smith MS; Koerber KL; Pagano JS
J Infect Dis; 1994 Jan; 169(1):184-8. PubMed ID: 7506280
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
Mohri H; Singh MK; Ching WT; Ho DD
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):25-9. PubMed ID: 7678340
[TBL] [Abstract][Full Text] [Related]
13. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Larder BA; Kellam P; Kemp SD
Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
[TBL] [Abstract][Full Text] [Related]
14. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.
Lacey SF; Larder BA
J Virol; 1994 May; 68(5):3421-4. PubMed ID: 7512165
[TBL] [Abstract][Full Text] [Related]
15. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
Demeter LM; Nawaz T; Morse G; Dolin R; Dexter A; Gerondelis P; Reichman RC
J Infect Dis; 1995 Dec; 172(6):1480-5. PubMed ID: 7594706
[TBL] [Abstract][Full Text] [Related]
16. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
[TBL] [Abstract][Full Text] [Related]
17. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
[TBL] [Abstract][Full Text] [Related]
18. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
Reichman RC; Tejani N; Lambert JL; Strussenberg J; Bonnez W; Blumberg B; Epstein L; Dolin R
Antiviral Res; 1993 Apr; 20(4):267-77. PubMed ID: 8097906
[TBL] [Abstract][Full Text] [Related]
19. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Miranda LR; Götte M; Liang F; Kuritzkes DR
Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
Winters MA; Shafer RW; Jellinger RA; Mamtora G; Gingeras T; Merigan TC
Antimicrob Agents Chemother; 1997 Apr; 41(4):757-62. PubMed ID: 9087484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
